MLYS - Mineralys Therapeutics Inc
27.51
-0.980 -3.562%
Share volume: 603,761
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$28.49
-0.98
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-13-2024 | 11-12-2024 | 02-12-2025 | 05-12-2025 | 11-10-2025 | 03-12-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 35.362 M | 45.168 M | 60.106 M | 51.767 M | 44.447 M | 41.131 M | 38.280 M | |
| Selling general and admin | 4.608 M | 5.895 M | 6.121 M | 7.198 M | 6.568 M | 9.681 M | 13.878 M | |
| Research and development | 30.754 M | 39.273 M | 53.985 M | 44.569 M | 37.879 M | 31.450 M | 24.402 M | |
| Total expenses | 35.362 M | 45.168 M | 60.106 M | 51.767 M | 44.447 M | 41.131 M | 38.280 M | |
| 27.73% | 33.07% | -13.87% | -14.14% | -7.46% | -6.93% | |||
| Operating income | -35.362 M | -45.168 M | -60.106 M | -51.767 M | -44.447 M | -41.131 M | -38.280 M | |
| Ebit | -35.361 M | -45.166 M | -60.116 M | -51.755 M | -44.450 M | -41.127 M | -38.279 M | |
| Pretax income | -31.508 M | -41.014 M | -56.342 M | -48.946 M | -42.211 M | -36.932 M | -32.234 M | |
| 30.17% | 37.37% | -13.13% | -13.76% | -12.51% | -12.72% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -31.508 M | -41.014 M | -56.342 M | -48.946 M | -42.211 M | -36.932 M | -32.234 M | |
| -30.17% | -37.37% | 13.13% | 13.76% | 12.51% | 12.72% |